Espey Mfg. & Electronics GAAP EPS of $0.75 misses by $0.13, revenue of $10.61M misses by $2.29M

Espey Mfg. & Electronics (ESP) reported Q1 GAAP EPS of $0.75, missing estimates by $0.13, with revenue of $10.61M, up 16.7% Y/Y but missing by $2.29M. Shares fell 3.97%.

Original reporting
Published Nov 13, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ESP
Bearish
medium confidence
Mentioned
$ESP
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ESPBearishMed
01

Why it matters

The earnings miss is likely to trigger a short‑term decline in the stock price, especially given the 3.97% drop already observed.

02

Market read

The primary relevance is to traders holding or considering ESP, as the earnings miss may affect short‑term price action.

03

What to watch

Potential hidden upside from upcoming contract announcements or cost‑reduction initiatives not disclosed in this brief.

Relevance 6/10Novelty 6/10Timing: after-hours reaction

Background

Espey Mfg. & Electronics released its Q1 earnings, reporting a miss on both earnings per share and revenue versus expectations.

Company-level read

Ticker impact

$ESPBearishMedium confidence
Context

Q1 GAAP EPS of $0.75 missed expectations by $0.13 and revenue of $10.61M missed by $2.29M, driving a 3.97% share decline.

Expected impact

downward pressure as the market prices in the earnings miss

Evidence & confidence

The miss on both EPS and revenue is a fresh primary disclosure for a micro‑cap; investors typically react negatively to such surprises.

Market effects

Minimal impact on the broader electronics manufacturing sector; the miss is company‑specific.

Limited to U.S. small‑cap investors; no broader regional effect.

Low; the company is a niche micro‑cap with limited global exposure.

Counterpoint

If the miss is viewed as a temporary setback and the company has a strong backlog, the stock could rebound on future guidance.

Key entities

  • Espey Mfg. & Electronics

    Micro‑cap electronics manufacturer reporting Q1 results.

Related articles

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).